We are signatories to the San Francisco Declaration on Research Assessment (DORA) http://www.ascb.org/dora/ and support its aims to improve how the quality of research is evaluated. Bibliometrics can be used as indicators of general interest and trends, but simple numbers do not replace your own critical evaluation of an article and certainly cannot indicate the value of research. PRNANO Editorial Policy Version 040618 Precision Nanomedicine (PRNANO) endorses editorial policies recommended by the Committee of Publication Ethics (COPE) and the International Committee of Medical Journal Editors (ICMJE) where applicable. Authorship Authorship of the work should fulfill the following criteria: Substantial contributions to the conception, design, the acquisition, analysis, or interpretation of data. Drafting the work or revising it critically for important intellectual content. Gives approval of the submitted manuscript and subsequent versions to be published. Authors and co-authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. It is the sole responsibility of contributors to determine who are the authors of the manuscript submitted to the journal. Those, who do not meet all four criteria, but contributed to the work should also be acknowledged. All co-authors must agree to publication and have given the corresponding author the authority to act on their behalf in all matters pertaining to publication. The corresponding author is responsible for informing the co-authors of the manuscript status throughout the submission, review and production process. Addition or Removals of Authors: The authors request for addition or removal of an author should be properly justified in writing via email sent to editor@precisionnanomedicine.com. Please note that a change in authorship (order of listing, addition or deletion of a name, or corresponding author designation) after submission of the manuscript will be implemented only after receipt of signed statements of agreement from all parties involved (all listed authors and the author to be removed or added). We encourage authors to use ORCID (http://orcid.org/) and include their ORCID identifier on submission to enable transparent and trustworthy connections between researchers. Please visit the ORCID page for more information.
Before Submission Authors may request a preliminary scope assessment by emailing the title, list of authors, and the abstract of their manuscript to editor@precisionnnanomedicine.com. This is not a requirement, only an option to accelerate the process. There can be only one corresponding author, but PRNANO acknowledges all authors that are marked as equally contributed to this work. Use of either US or UK English is acceptable, but only one language version and one reference style should be used within the same document. Previously Published Studies and Data PRNANO does not accept submissions as original that have already been published, or under consideration elsewhere in the peer-reviewed literature. All figures and tables should be original and should not have been published in any previous publications. However, PRNANO does support authors who wish to share their work early through deposition of manuscripts with preprint servers such as biorxiv or arxiv, have been presented at conferences or published as a thesis. Replication studies must be clearly identified as such. Authors may request updating their work previously published online as Articles in Progress in PRNANO before it edited into an issue, although this fact will be clearly marked. Submission All manuscripts are handled online through the journal manuscript submission system. Submission of a manuscript to PRNANO implies that the manuscript (or one with substantially the same content, by any of the authors) has not been previously published in any language anywhere, and that it is not under simultaneous consideration by any other journal. First, the Editor-in-Chief decides whether the manuscript is within the scope of the journal. Manuscripts outside the scope of the journal will be returned to the corresponding author with justification. This decision is based on the following criteria: 1) Relevance: the content conforms to the scope of PRNANO, i.e., the manuscript is of INTERDISCIPLINARY nature and overlap nanotechnology with biology, and/or medicine. 2) Significance: The work must ADVANCE THE FIELD AND IMPROVE SCIENTIFIC KNOWLEDGE. Accounts of research must appeal to a broad readership. 3) Ethical Requirements: The manuscript follows guidelines of national and international ethical standards for studies with human and/or animal subjects (where applicable). In case that these basic criteria have not been met, the manuscript will be sent back to the authors with recommendations. The authors have the opportunity to resubmit the manuscript after revision.
Additional requirements: 4) Synthesis of nanotechnology-based medicines (i.e., substances that promote healing) MUST accompany bioavailability and toxicity data as well as their evaluation. 5) Experimental studies must include at least in vitro results, although in vivo is preferred. Using nano-characterization methods does not automatically qualify as nanomedicine. All submissions (within the scope of the journal) are checked for similarities and overlap using Crosscheck software. There are no numeric thresholds for similarity indices, and scientific overlap is always evaluated by the EiC before assigning the manuscript to Associate Editors. Peer review: If all criteria have been met, reviews, articles, and short communications undergo a singleblinded peer review by at least two independent reviewers. The purpose of the peer-review is to assess scientific merit and improve the manuscript. Opinion Papers (Perspectives, Opinions, Comments and Letters) are reviewed by the Editor-in-Chief, an Associate Editor, and at least one independent reviewer, preferably a Board Member. Case Studies are reviewed by the EiC and an expert Board member, and/or invited peers. Associate Editors receive and review manuscripts within their area of expertise and have the right to make recommendations to the EiC immediately to Accept, Revise, or Reject manuscripts, based on their scientific merit. Manuscripts with Reject with Hope decisions in principle will be reassigned to the same Editor when resubmitted. All editors and reviewers must submit justifications to the Journal Office in writing. AEs also invite reviewers, who expected to make an objective, impartial evaluation of the scientific merits of the manuscript and suggest improvements. The task of reviewers is to advise the handling Editor regarding the paper. Decisions Decisions are finalized by the Editor-in-Chief based on the Associate Editors recommendation, justification, and the reviewers' comments. PRNANO aspires to notify authors within 3 weeks from the submission date, but as soon as it is possible. The journal uses the following decisions: Accept, Revise, Reject, Reject with Hope, and Reject with Internal Review Accepted manuscripts enter the publishing process described below. Promising ideas and manuscripts will be marked as early stage ones ( Reject with Hope decision) and may be reconsidered when they are up to standards. Peer reviewed manuscripts with a full Reject decision should be published elsewhere. Revise indicates that a peer-reviewed manuscript may be considered for publication, but it has to be improved first and will be sent out to peer-review, the result of which are communicated by the Editors through the submission system. Authors have the right to discuss decisions and reviewer comments in a separate letter, but they have to address all remarks and have to revise their manuscript. The purpose of this closed discussion between authors, editors, and reviewers is the betterment of manuscript and improve scientific merit. During this discussion all scientific arguments will be
considered. There is no deadline to resubmit revised manuscripts, but after three months all manuscripts will be considered new submissions and receive new codes. The Managing Editor supervises the submission system including reviewer invitations and responses and in general - operates the submission system in an optimal manner. Finalizing an accepted manuscript Authors of manuscripts accepted for publication supposed to resubmit the final version in a simple MSWord document. PRNANO encourages authors not to worry about the appearance of their document, instead concentrate on giving it proper structure (see Authors Guide). Detailed instructions, structural guide, and style example may be found here. (https://science.ai/documentation/ds3.) Following the style is highly recommended although not mandatory and authors may request outside typesetting at a minimal extra cost, which may somewhat delay publication. Precision Nanomedicine uses Artificial Intelligence for instantly converting DS3 formatted manuscripts to articles. Copyediting and Proofreading Accepted MSWord manuscripts undergo copyediting than are sent back by the Editorial Office to the corresponding author for final approval. Authors are advised carefully check the copyedited version. Please, turn on the TRACK CHANGES command and correct occasional typos and linguistic differences before publication. The corresponding author should return the manuscript with the corrections to the journal office as soon as possible. Authors may occasionally be asked to provide additional comments and explanations on linguistic or technical aspects to clarify details. Finally, compliance with style requirements will be certified by an Office member before the manuscript is converted for public display on the journal home page. Publication Online Precision Nanomedicine uses Artificial Intelligence to convert proofread DS3 style manuscripts into HTML containing rich schema.org markup. This structured, semantic markup understood by search engines increases discoverability by 50%. The process will optimize the articles for accessibility, discoverability, and long-term preservation. Articles are published online approx.1-3 days after final versions have received from the authors, depending on the technical quality of the manuscript. After pagination, formatting and markup only minor linguistic and typing corrections are possible. Accepted papers go online with assigned issue and page numbers and DOI. A downloadable version in Adobe Acrobat PDF format is also provided. Articles receive continuous page numbers within the actual calendar year of publication, based on the pages of their PDF versions. Issues are compiled quarterly to offer topical overview for readers. Additional NLM-based classification keywords and brief summaries from the Clinical Editor are also added to published articles. Finally, the articles are organized into volumes (year of publication) and issues (according to topics), including original page numbers and digital object identifiers for each article.
Errata Errors detected in published articles should be reported immediately and the corresponding author should send the appropriate corrected material to the Editorial Office. The corrections will, in accordance with the Editors-in-Chief s decision, be published as soon as possible. Authors, who request Articles in Progress status may update their work, but major modifications might require retraction of the original article. Copyright Authors retain the ownership of their copyright before online publication. Once the paper is published, Author(s) and users - Under the Creative Commons CC BY SA 4.0 license - are free to share (copy and redistribute the contribution in any medium or format) and adapt (remix, transform, and build upon) the material, under the following conditions: 1. They must give appropriate credit to the contribution, provide a link to the license, and indicate if changes were made. This can be done in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. 2. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. Scientific misconduct Scientific misconduct is defined as the fabrication or falsification of research results, intellectual property theft (plagiarism), or other practices that deviate from commonly accepted standards within the academic community for scientific work on the proposal, conducting or reporting of research. In cases where there is a suspicion or allegation of scientific misconduct or fraudulent research in submitted or published manuscripts, the PRNANO Editors reserve the right to impose sanctions on the authors. This may include the following measures: Immediate rejection of the manuscript. Retraction of a published manuscript. Sharing concerns with the authors' academic, sponsoring or funding institution, or other appropriate authority for investigation. Informing editors of other journals. Precision Nanomedicine publishes only manuscripts not previously published, nor under consideration for publication at any other journal. Multiple submissions or redundant publications (repackaging of data by the same authors with different formulation) will be rejected. Where this is detected only after publication, the journal reserves the right to retract the article and to publish an appropriate Retraction Note. Retraction Policy Serious errors or violation of professional and ethical standards in a published manuscript will result in the retraction of the article. This will occur where the article: Data turns out to be falsified or fabricated; Serious experimental errors were detected at a later time; Conclusions were incorrect due to experimental errors identified later;
Is clearly defamatory or infringes on others' legal rights; Is the subject of a court order, or there is good reason to believe that it will be; If acted upon, could pose a serious health or security risk. In all of these cases, all co-authors will be informed about the retraction. A Retraction Note, detailing the reasons for retraction, will be linked to the original article. Conflict of Interest A conflict of interest for a scientific journal is anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, review, or publication of research findings, or of articles that comment on or review research findings. Potential conflicts of interest are manifested when an author, editor or reviewer has financial, personal or professional interests in a publication that might influence their scientific judgment. To encourage transparency without impeding publication, all authors, reviewers and editors must declare any association that poses a conflict of interest in connection with the manuscript. No contractual relations or proprietary considerations that would affect the content of the publication or the evaluation of the manuscript should exist. It is the responsibility of the authors to disclose any funding sources for the project, or other relevant relationships in the manuscript before the Reference section. The editors must consider whether there are any conflicts of interest relevant to them. Where an Editor believes that the conflict will impair their judgment, they should decline to handle the manuscript. Reviewers must disclose all conflicts of interests or relationships to the author/s. If they feel that they are unable to review a paper objectively because of any competing interest, they should notify the Editors-in-Chief. Please, also refer to our Publication Ethics and Malpractice Statement [LINK]. Lajos P Balogh Editor-in-Chief Andover, Massachusetts, USA T: +1-617-309-7621 editor@precisionnanomedicine.com